Protagonist Therapeutics, Inc. (PTGX) Financials
PTGX Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 358.0 million | 21.3 million |
2023-09-30 | 330.0 million | 27.9 million |
2023-06-30 | 320.5 million | 26.4 million |
2023-03-31 | 239.9 million | 23.7 million |
PTGX Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | 16.9 million | 6.6 million |
2023-09-30 | -27.0 million | 6.8 million |
2023-06-30 | -26.4 million | 8.3 million |
2023-03-31 | -34.4 million | 7.6 million |
PTGX Net Income
No data available :(
PTGX Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 341.6 million | - | 1.1 million |
2023-09-30 | 322.7 million | - | 1.8 million |
2023-06-30 | 313.4 million | - | 2.4 million |
2023-03-31 | 230.8 million | - | 3.1 million |
PTGX Shares Outstanding
PTGX Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 19000 | 28.9 million | 8.1 million | - |
2023-09-30 | 404000 | 30.7 million | 7.7 million | - |
2023-06-30 | 176000 | 33.2 million | 9.2 million | - |
2023-03-31 | 10000 | 27.4 million | 8.6 million | - |
PTGX Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 60.0 million | 832000 |
2023-09-30 | - | 827000 |
2023-06-30 | - | 821000 |
2023-03-31 | - | 832000 |
PTGX
Price: $25.54
52 week price:
Earnings Per Share: -1.39 USD
P/E Ratio: -9.97
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 966400
Ebitda: -4.9 millionMarket Capitalization: 1.6 billion